A Phase I Study of Cetuximab and Lapatinib In Patients with Advanced Solid Tumor Malignancies

BACKGROUND: Acquired resistance to anti-EGFR therapy may be due to EGFR-ErbB2 heterodimerization and pathway reactivation. In pre-clinical studies. inhibiting ErbB2 blocked this resistance mechanism and re-sensitized cells to anti-EGFR therapy. Cetuximab targets the EGFR receptor, whereas lapatinib...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Deeken, John F., Wang, Hongkun, Subramaniam, Deepa, He, Aiwu Ruth, Hwang, Jimmy, Marshall, John L., Urso, Christina E., Wang, Yiru, Ramos, Corinne, Steadman, Kenneth, Pishvaian, Michael J.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4424139/
https://ncbi.nlm.nih.gov/pubmed/25641763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29224
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars